Özgüroğlu, Mustafa
Istanbul University-Cerrahpaşa · Istanbul University
6 papers on CoChatORCID 0000-0002-8417-8628
Most cited papers
- Verified
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment
Cited by 4,593
- Verified
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine
Cancer Immunotherapy and BiomarkersLung Cancer Diagnosis and Treatment
Cited by 2,798
- Verified
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
Chi, K. N., Agarwal, N., Bjartell, A., Chung, B. H., Pereira de Santana Gomes, A. J., Given, R., Juárez Soto, Á., Merseburger, A. S., Özgüroğlu, M., Uemura, H., et al. (2019) · New England Journal of Medicine
Prostate Cancer Treatment and ResearchProstate Cancer Diagnosis and Treatment
Cited by 1,564
- Verified
Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
Spigel, D. R., Faivre-Finn, C., Gray, J. E., Vicente, D., Planchard, D., Paz-Ares, L., Vansteenkiste, J. F., Garassino, M. C., Hui, R., Quantin, X., et al. (2022) · Journal of Clinical Oncology
Lung Cancer Diagnosis and TreatmentCancer Immunotherapy and Biomarkers
Cited by 1,445
- Verified
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Hussain, M., Mateo, J., Fizazi, K., Saad, F., Shore, N., Sandhu, S., Chi, K. N., Sartor, O., Agarwal, N., Olmos, D., et al. (2020) · New England Journal of Medicine
PARP inhibition in cancer therapyProstate Cancer Treatment and Research
Cited by 792
- Verified
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: A multicentre, open-label, global, phase 3, randomised, controlled trial
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet
Cancer Immunotherapy and BiomarkersLung Cancer Treatments and Mutations
Cited by 789
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free